Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia

BMC Cancer

Table 3 Multivariate analysis of factors associated with abnormal cytological findings

	Abnormal Pap test result *
	n	(%)**	Adjusted OR	95% CI
HIV; immune status CD4 cell/mm ³ count
HIV-negative	241	(20.8)	Ref
HIV-positive, < 200	35	(16.2)	2.89	1.73-4.84
HIV-positive, 200 - 349	12	(5.6)	1.05	0.52-2.11
HIV-positive, 350 - 500	12	(5.6)	1.34	0.66-2.71
HIV-positive, > 500	9	(4.2)	1.41	0.63-3.16
HIV viral load copies/mL
HIV-negative	241	(20.8)	Ref
HIV-positive, <4,000	49	(22.7)	1.44	0.96-2.16
HIV-positive, 4,000-99,999	8	(3.7)	1.95	0.77-4.94
HIV-positive, >100,000	11	(5.1)	8.63	2.65-28.12
HIV and ART use
HIV-negative	241	(20.8)	Ref
HIV-positive, treatment with ART	57	(26.4)	1.57	1.06-2.32
HIV-positive, without treatment with ART	11	(5.1)	3.63	1.39-9.45

OR adjusted for age, marital status, age at first intercourse, the number of lifetime sexual partners, contraceptive methods used and smoking status, Papanicolaou test, CD4-count, HIV-viral-load and antiretroviral therapy or ART.
Values in bold = p < 0.05.
Pap test: Papanicolaou test, 95% CI: confidence interval, OR: odds ratio, HIV: Human Immunodeficiency Virus, ART: antiretroviral therapy, ASCUS: atypical squamous cells of undetermined significance, LSIL: low grade squamous intraepithelial lesion, HSIL: high grade squamous intraepithelial lesions.
*Includes ASCUS, LSIL and HSIL.
**Percentages were calculated regarding HIV-positive = 216 and HIV-negative n = 1,159.

ISSN: 1471-2407